Profile data is unavailable for this security.
About the company
Tanvex BioPharma, Inc. is a holding company. The Company and its subsidiaries are engaged in the research and development of biosimilar products, biological production processes, and the contract development and manufacturing of biological medicines. It excels in areas such as strain and cell-line development in both microbial and mammalian systems, cell culture, protein purification, process scale-up, drug substance and product manufacturing, and warehousing, sales, and distribution. Its product pipeline includes Neupogen (TX-01), Herceptin (TX-05), Neulasta (TX-04), Avastin (TX-16), and Perjeta (TX-52). The Company has two subsidiaries, namely Tanvex Biologies Corporation (Tanvex Taiwan) and Tanvex BioPharma USA, Inc. (Tanvex USA). Tanvex Taiwan is responsible for initial stage cell line development and bioprocess development, while Tanvex USA is responsible for further cell line and process development, scaling up the process to achieve commercialization and mass production.
- Revenue in TWD (TTM)34.56m
- Net income in TWD-1.81bn
- Incorporated2013
- Employees--
- LocationTanvex BioPharma IncFloor 4, Willow House, Cricket Square,P O Box 2804GRAND CAYMAN KY1-1112Cayman IslandsCYM
- Websitehttp://www.tanvex.com/
Mergers & acquisitions
| Acquired company | 6541:TAI since announced | Transaction value |
|---|---|---|
| Bora Biologics Co Ltd | 3.77% | 141.93m |
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Tanvex Biopharma Inc | 34.56m | -1.81bn | 10.50bn | -- | -- | 7.10 | -- | 303.86 | -12.99 | -12.99 | 0.2453 | 9.01 | 0.0097 | 0.2108 | 2.38 | -- | -50.72 | -49.24 | -55.58 | -53.18 | 24.17 | 49.20 | -5,232.64 | -10,835.34 | 3.32 | -139.19 | 0.5405 | -- | 174.11 | -- | -30.22 | -- | -8.09 | -- |
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 30 Jun 2024 | 0.00 | 0.00% |
